282 related articles for article (PubMed ID: 27619250)
1. Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions.
Corso CD; Bindra RS
Semin Radiat Oncol; 2016 Oct; 26(4):281-98. PubMed ID: 27619250
[TBL] [Abstract][Full Text] [Related]
2. Potential usefulness of radiosensitizers in glioblastoma.
Harasaki Y; Waziri A
Neurosurg Clin N Am; 2012 Jul; 23(3):429-37. PubMed ID: 22748655
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma. Part II: Future directions.
Salacz ME; Watson KR; Schomas DA
Mo Med; 2011; 108(4):289-91. PubMed ID: 21905448
[TBL] [Abstract][Full Text] [Related]
4. The Current State of Potential Therapeutic Modalities for Glioblastoma Multiforme: A Clinical Review.
Mohtashami E; Shafaei-Bajestani N; Mollazadeh H; Mousavi SH; Jalili-Nik M; Sahebkar A; Afshari AR
Curr Drug Metab; 2020; 21(8):564-578. PubMed ID: 32664839
[TBL] [Abstract][Full Text] [Related]
5. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
[TBL] [Abstract][Full Text] [Related]
6. Roles of Valproic Acid in Improving Radiation Therapy for Glioblastoma: a Review of Literature Focusing on Clinical Evidence.
Ochiai S; Nomoto Y; Yamashita Y; Watanabe Y; Toyomasu Y; Kawamura T; Takada A; Ii N; Kobayashi S; Sakuma H
Asian Pac J Cancer Prev; 2016; 17(2):463-6. PubMed ID: 26925628
[TBL] [Abstract][Full Text] [Related]
7. Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs.
von Neubeck C; Seidlitz A; Kitzler HH; Beuthien-Baumann B; Krause M
Br J Radiol; 2015 Sep; 88(1053):20150354. PubMed ID: 26159214
[TBL] [Abstract][Full Text] [Related]
8. Management of Glioblastoma Multiforme in Elderly Patients: A Review of the Literature.
Halani SH; Babu R; Adamson DC
World Neurosurg; 2017 Sep; 105():53-62. PubMed ID: 28465276
[TBL] [Abstract][Full Text] [Related]
9. [New therapeutic options in therapy of glioblastoma multiforme].
Lakomý R; Burkon P; Burkonová D; Jancálek R
Klin Onkol; 2010; 23(6):381-7. PubMed ID: 21351415
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in therapy for glioblastoma.
Clarke J; Butowski N; Chang S
Arch Neurol; 2010 Mar; 67(3):279-83. PubMed ID: 20212224
[TBL] [Abstract][Full Text] [Related]
11. Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.
Ung N; Yang I
J Neurooncol; 2015 Jul; 123(3):473-81. PubMed ID: 26070553
[TBL] [Abstract][Full Text] [Related]
12. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
13. DTCM-glutarimide Delays Growth and Radiosensitizes Glioblastoma.
Roberto GM; Paiva HH; Botelho de Souza LE; Pezuk JA; Vieira GM; de Oliveira HF; Umezawa K; Tone LG; Brassesco MS
Anticancer Agents Med Chem; 2018; 18(9):1323-1329. PubMed ID: 29683097
[TBL] [Abstract][Full Text] [Related]
14. Cellular-based immunotherapies for patients with glioblastoma multiforme.
Xu X; Stockhammer F; Schmitt M
Clin Dev Immunol; 2012; 2012():764213. PubMed ID: 22474481
[TBL] [Abstract][Full Text] [Related]
15. Cold Atmospheric Plasma as an Adjunct to Immunotherapy for Glioblastoma Multiforme.
Almeida ND; Klein AL; Hogan EA; Terhaar SJ; Kedda J; Uppal P; Sack K; Keidar M; Sherman JH
World Neurosurg; 2019 Oct; 130():369-376. PubMed ID: 31284051
[TBL] [Abstract][Full Text] [Related]
16. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
[TBL] [Abstract][Full Text] [Related]
17. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review.
Anjum K; Shagufta BI; Abbas SQ; Patel S; Khan I; Shah SAA; Akhter N; Hassan SSU
Biomed Pharmacother; 2017 Aug; 92():681-689. PubMed ID: 28582760
[TBL] [Abstract][Full Text] [Related]
18. Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy.
Antonopoulos M; VAN Gool SW; Dionysiou D; Graf N; Stamatakos G
Anticancer Res; 2019 Apr; 39(4):2043-2051. PubMed ID: 30952748
[TBL] [Abstract][Full Text] [Related]
19. Combining immunotherapy with radiation for the treatment of glioblastoma.
Chow KK; Hara W; Lim M; Li G
J Neurooncol; 2015 Jul; 123(3):459-64. PubMed ID: 25877468
[TBL] [Abstract][Full Text] [Related]
20. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
